Answers are grounded in this paper and cite their sources.
The results of the analysis of the range, economic accessibility and consumption of angiotensin II receptor blockers (ARBs II) compared to ACE inhibitors within 2008-2013 have been considered. The choice of the optimal trade names (TN) has been substantiated according to the results of the “cost minimization” pharmacoeconomic analysis and the missed opportunities index. During the study period there was the increase in the range of ARBs II at the pharmaceutical market of Ukraine mainly due to foreign drugs. Drugs of ARBs II are characterized by lower availability for an average Ukrainian compared to ACE inhibitors. In the dynamics of the years the consumption volumes of ARBs II increased, but they were significantly inferior to the volume of ACE inhibitors consumption. During the research period the leaders of consumption were drugs of losartan, valsartan and candesartan, which were mostly generics. According to the results of the pharmacoeconomic analysis and the calculation of the missed opportunities some cheaper drugs of ARBs II have been identified. Using these drugs compared to more expensive ones allows to treat additionally a certain number of patients.
No takes yet. Share an insight, caveat, or question.
Mishchenko et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: